TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells

Oct 1, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·S TahmasebiA Esmaeilzadeh

Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors

Aug 1, 2020·Oncogene·Maolin GeHan Liu

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity

Feb 20, 2019·Leukemia·Clara BuenoPablo Menéndez

Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.

Sep 17, 2020·Oncoimmunology·Marion AlcantaraEmanuela Romano

Gene modification strategies for next-generation CAR T cells against solid cancers.

May 20, 2020·Journal of Hematology & Oncology·Yonggui TianYi Zhang

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.

Apr 4, 2020·Leukemia·Laura GodfreyThomas A Milne

Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis.

Nov 3, 2020·Frontiers in Immunology·You ZhaiWei Zhang

Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.

Nov 21, 2020·British Journal of Haematology·Hind RafeiKatayoun Rezvani

mTORC1-mediated amino acid signaling is critical for cell fate determination under transplant-induced stress.

Nov 30, 2020·FEBS Letters·Xiaoyan ChengHan Liu

Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Jan 6, 2021·Frontiers of Medicine·Jianfeng LiSaijuan Chen

Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy.

Nov 13, 2020·Critical Reviews in Oncology/hematology·Stella Bouziana, Dimitrios Bouzianas

Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.

Dec 12, 2020·International Journal of Molecular Sciences·Elzbieta PorebaJulia Durzynska

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.

Mar 2, 2021·Frontiers in Immunology·Xinjie XuYuhua Li

MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.

May 8, 2020·Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms·Siobhan Rice, Anindita Roy

A pan-cancer perspective analysis reveals the opposite prognostic significance of CD133 in lower grade glioma and papillary renal cell carcinoma.

Apr 22, 2021·Science Progress·Haiwei WangHua Cao

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia.

May 1, 2021·Cancers·Fabian RieggMelanie Märklin

Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond.

Jun 22, 2021·Current Opinion in Pharmacology·Victor MorenoEmiliano Calvo

Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.

Jul 24, 2021·Experimental Hematology·Wenjuan LiaoPatricia Ernst

CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Dec 19, 2021·Frontiers of Medicine·Jian-Qing MiSaijuan Chen

❮ Previous

Next ❯

Methods Mentioned

FACS

ELISA

flow cytometry

xenograft

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells

Abstract

References

Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.

The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4

Chimeric antigen receptor T cells for sustained remissions in leukemia

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers

Citations

Immunobiology of chimeric antigen receptor T cells and novel designs

MLL -Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?

Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia

New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry.

Identification of co-expressed genes associated with MLL rearrangement in pediatric acute lymphoblastic leukemia.

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.